Patents for A61P 35 - Antineoplastic agents (221,099)
06/2007
06/12/2007US7230139 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
06/12/2007US7230132 Aryl N-cyanoguanidines and methods related thereto
06/12/2007US7230106 Process for the preparation of inhibitors of macrophage migration inhibitory factor
06/12/2007US7230105 9-aminoacridine derivatives and process for the preparation thereof
06/12/2007US7230096 derivatives of 3'-amino LacNAc for treatment of inflammation, septic shock, cancer, autoimmune diseases, rheumatoid arthritis and multiple schlerosis
06/12/2007US7230088 Compounds for dual photodiagnosis and therapy
06/12/2007US7230085 Anti-DOTA antibody
06/12/2007US7230084 Therapeutic using a bispecific antibody
06/12/2007US7230083 Genetic engineered vitronectin receptors; restenosis therapy, anticancer agents
06/12/2007US7230031 Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
06/12/2007US7230026 Selected fused pyrrolocarbazoles
06/12/2007US7230021 Therapy for immunology sensitive disease; marine animal extract
06/12/2007US7230015 Potassium/sodium channel blockers; for treatment of multiple sclerosis, spinal cord injury, traumatic brain injury, stroke, bladder irritation and dysfunction, neuropathic pain and chemokine-induced pain
06/12/2007US7230013 Administering taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions for inhibiting tumor growth
06/12/2007US7230009 Pyridoxal analogues and methods of treatment
06/12/2007US7229978 Chloromethylating an alcohol or phenol, especially camptothecin, propofol, etoposide, vitamin E, or cyclosporin A, and reacting the product with phosphoric acid in the presence of a base in a suitable polar aprotic solvent
06/12/2007US7229974 Used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors
06/12/2007US7229969 Dipeptidyl peptidaseIV and alanyl-aminopeptidase inhibitors
06/12/2007US7229822 Melanoma differentation associated gene-5 and vectors and cells containing same
06/12/2007US7229780 Monoclonal antibody against ovarian carcinoma
06/12/2007US7229770 YKL-40 as a marker and prognostic indicator for cancers
06/12/2007US7229755 Isolating a biological specimen from a human; testing the specimen for an alteration in a human MSH2 nucleotide sequence or its expression product; comparing the results obtained with the results obtained from a wild type control
06/12/2007US7229628 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
06/12/2007US7229624 Ordered molecular presentation of antigens, method of preparation and use
06/12/2007US7229623 Her-2/neu fusion proteins
06/12/2007US7229620 for radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer
06/12/2007US7229607 Treatment of respiratory disease
06/12/2007CA2393758C Unsaturated 14,15-cyclopropano-androstanes
06/12/2007CA2354023C Phenylglycine derivatives
06/12/2007CA2287257C 1,2,4-benzotriazine oxides formulations
06/12/2007CA2214649C Antigen presenting system and methods for activation of t-cells
06/12/2007CA2198005C Pyrazolo[3,4-g]quinoxaline compounds which inhibit pdgf receptor protein tyrosine kinase
06/12/2007CA2173975C Recombinant adenoviral vector and methods of use
06/12/2007CA2113712C Papilloma virus vaccine
06/12/2007CA2072620C Urinary tumor associated antigen, antigenic subunits uses and methods of detection
06/12/2007CA1341530C Inhibitors of angiogenin
06/07/2007WO2007065100A1 Pyrrolotriazine kinase inhibitors
06/07/2007WO2007065023A2 Processes for obtaining lignan extracts and compositions containing the lignan extracts
06/07/2007WO2007064993A2 Bicyclic protein kinase inhibitors
06/07/2007WO2007064872A2 Urea compounds useful in the treatment of cancer
06/07/2007WO2007064797A2 Inhibitors of c-met and uses thereof
06/07/2007WO2007064753A2 Cancer treatment method
06/07/2007WO2007064345A2 Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
06/07/2007WO2007063946A1 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
06/07/2007WO2007063903A1 Novel peptide compound
06/07/2007WO2007063293A1 Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
06/07/2007WO2007063291A1 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
06/07/2007WO2007063124A1 Use of a compound comprising a camptothecin derivative for preparing pharmaceutical formulations useful in the treatment of melanoma
06/07/2007WO2007063013A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
06/07/2007WO2007062875A1 Heteroaromatic sulfonamide prodrugs
06/07/2007WO2007062805A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS
06/07/2007WO2007062568A1 Compounds used as mammalian cell amp-activated protein kinase(ampk) activators and their preparation methods and usages
06/07/2007WO2007062564A1 Lyophilized taxane-liposome composition and its preparing process
06/07/2007WO2007062466A1 Demibodies: dimerisation-activated therapeutic agents
06/07/2007WO2007062459A1 Selective kinase inhibitors based on pyridine scaffold
06/07/2007WO2007048088A3 Method of inhibiting flt3 kinase
06/07/2007WO2007044426A3 Pyrazolopyrimidines as protein kinase inhibitors
06/07/2007WO2007044401A3 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/07/2007WO2007043715A9 Rna-binding peptide
06/07/2007WO2007042786A3 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
06/07/2007WO2007038073A3 Mutations and polymorphisms of hdac11
06/07/2007WO2007024744A3 Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
06/07/2007WO2007015870A3 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
06/07/2007WO2007002258A3 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
06/07/2007WO2006113495A3 Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
06/07/2007WO2006099313A3 Phosphate conjugates of prenylation inhibitors
06/07/2007WO2006081331A3 Quinoxaline derivatives as antitumor agents
06/07/2007WO2006042100A3 Method for the treatment of polycystic kidney disease
06/07/2007WO2005016234A3 Compositions, methods, apparatuses, and systems for singlet oxygen delivery
06/07/2007US20070129427 Novel compound and pharmaceutical composition
06/07/2007US20070129411 Treatment of proliferative diseases with epothilone derivatives and radiation
06/07/2007US20070129399 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
06/07/2007US20070129365 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof
06/07/2007US20070129348 Receptor antagonist
06/07/2007US20070129318 Antisense oligonucleotide having anticancerous activity
06/07/2007US20070129317 Use of boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity
06/07/2007US20070129311 Compounds comprising two human GlxI inhibitors covalently linked via a diacid where each of the inhibitors may be the same or different and is an S-substituted glutathione or a prodrug thereof having a gamma-glutamyl amino group; length >50 Angstroms; antitumor, -carcinogenic, -proliferative agents
06/07/2007US20070129300 Cytotoxic factors for modulating cell death
06/07/2007US20070129289 Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
06/07/2007US20070129285 Protein a compositions and methods of use
06/07/2007US20070128695 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
06/07/2007US20070128672 Complementarity determining region (CDR); cancer, rheumatoid arthritis; immunology
06/07/2007US20070128645 Use of KIAA0172 gene in treatment and diagnosis of diseases as well as in pharmaceutical development
06/07/2007US20070128616 Aggrecanase molecules
06/07/2007US20070128603 Diagnostic and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
06/07/2007US20070128591 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
06/07/2007US20070128212 Ceramidase inhibitor
06/07/2007US20070128207 Method of selecting wt1 vaccine adaptive patient
06/07/2007US20070128203 Anti-integrin antibodies, compositions, methods and uses
06/07/2007US20070128202 inhibiting growth of cancerous cells using an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas
06/07/2007US20070128201 Combined use of ecteinascidin-743 and platinum antineoplastic compounds
06/07/2007US20070128198 Compositions comprising antibodies to human fgl2
06/07/2007US20070128197 Monoclonal antibody or an antigen-binding fragment thereof which binds to human VEGF-B (vascular endothelial growth factor) produced by hybridoma; neovascularization diseases; antitumor, anticarcinogenic, antiinflammatory, and antimetastasis agents; rheumatoid arthritis; angiogenesis inhibitors
06/07/2007US20070128192 Human antibody molecules for il-13
06/07/2007US20070128188 For stimulating release of tumor necrosis factor and/or cellular prolifefration/differentiation of chondrocytes by contacting blood w/polypeptide; diagnosis cancer
06/07/2007US20070128115 Pathological tissue detection and treatment employing targeted benzoindole optical agents
06/07/2007US20070128112 Fully human monoclonal antibodies that inhibit neovascularization of solid tumors; assaying for MCP-1; cancer diagnosis; may be conjugated to a chemotherapeutic agent such as taxol, doxorubicin, cis-platinum, and 5-fluorouracil.
06/07/2007US20070125613 Impact absorbent assembly in slope protection systems
06/07/2007CA2657452A1 Immunoconjugate for human cd66 for the treatment of multiple myeloma and other haematological malignancies
06/07/2007CA2632279A1 Heteroaromatic sulfonamide prodrugs